Press release 📈 Stocks 🌍 United States

Intellia Therapeutics Appoints Dr. Jing Marantz as Chief Medical Officer

Intellia Therapeutics taps industry veteran Dr. Jing L. Marantz to lead its medical and regulatory strategy as the company advances its CRISPR-based gene editing pipeline.

📅 October 13, 2026 🕐 1 min read

1 assets impacted (Stocks). Net bias: 0 Bullish, 0 Bearish, 1 Neutral. Strongest signal: NTLA → 2/10 (60% confidence).

📊 Affected Assets (1)

NTLA

Neutral 🤖 60%

📅 Short-term 🌍 US · Explicit

Appointment of a new Chief Medical Officer is a leadership change with no direct financial impact, likely neutral for the stock.

🎯 Key Takeaways

Dr. Jing L. Marantz joins Intellia with over 25 years of experience in drug development and rare disease therapies.
The appointment strengthens Intellia's leadership team as it continues to advance its CRISPR gene editing platform.
Marantz will assume responsibility for the company's translational, development, regulatory, and medical affairs functions.

📝 Executive Summary

Intellia Therapeutics has named Dr. Jing L. Marantz as its new Executive Vice President and Chief Medical Officer, effective October 26, 2026. Dr. Marantz brings over 25 years of biopharmaceutical experience to the CRISPR-focused firm, where she will oversee translational, regulatory, and medical affairs.

❓ FAQ

Who is the new Chief Medical Officer at Intellia Therapeutics?

Dr. Jing L. Marantz, M.D., Ph.D., has been appointed as the new Executive Vice President and Chief Medical Officer, effective October 26, 2026.

📰 Related Articles

🏷️ Tags

📰 Source

🔗 View Original Article